Sungmin Woo
YOU?
Author Swipe
View article: ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer
ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer Open
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) computed tomography (CT), and whole-body magnetic resonance imaging (WB-MRI) are superior to conventional CT and bone scan imaging for detecting metastatic diseas…
View article: Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee
Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee Open
mpMRI, VI-RADS, and nacVI-RADS represent essential tools for enhancing risk stratification and personalising BC management in clinical urology practice. Their integration into multidisciplinary workflows has the potential to improve outcom…
View article: Changes in prostate volume during prostate SBRT delivered on an MR-Linac and correlation with acute toxicity
Changes in prostate volume during prostate SBRT delivered on an MR-Linac and correlation with acute toxicity Open
View article: Correction to: Pictorial review of multiparametric MRI in bladder urothelial carcinoma with variant histology: pearls and pitfalls
Correction to: Pictorial review of multiparametric MRI in bladder urothelial carcinoma with variant histology: pearls and pitfalls Open
View article: Reply to Francesco Montorsi, Giuseppe Rosiello, Pietro Scilipoti, Marco Moschini, and Andrea Salonia’s Letter to the Editor re: Valeria Panebianco, Alberto Briganti, Jason Efstathiou, et al. The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the American College of Radiology VI-RADS Steering Committee. Eur Urol 2024;86:485–7
Reply to Francesco Montorsi, Giuseppe Rosiello, Pietro Scilipoti, Marco Moschini, and Andrea Salonia’s Letter to the Editor re: Valeria Panebianco, Alberto Briganti, Jason Efstathiou, et al. The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the American College of Radiology VI-RADS Steering Committee. Eur Urol 2024;86:485–7 Open
View article: Supplemental Figure 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Supplemental Figure 1
View article: Supplemental Table 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Table 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Supplemental Table 1
View article: Supplemental Figure 4 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 4 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Supplemental Figure 4
View article: Supplemental Table 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Table 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Supplemental Table 3
View article: Supplemental Table 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Table 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Supplemental Table 2
View article: Supplemental Figure 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Supplemental Figure 2
View article: Supplemental Table 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Table 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Supplemental Table 1
View article: Supplemental Figure 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Supplemental Figure 2
View article: Supplemental Figure 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Supplemental Figure 3
View article: Supplemental Table 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Table 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Supplemental Table 3
View article: Data from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Data from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Purpose:Patients with microsatellite instability–high/mismatch repair-deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab. We define the genomic features, clinical course, and r…
View article: Supplemental Figure 4 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 4 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Supplemental Figure 4
View article: Data from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Data from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Purpose:Patients with microsatellite instability–high/mismatch repair-deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab. We define the genomic features, clinical course, and r…
View article: Supplemental Table 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Table 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Supplemental Table 2
View article: Supplemental Figure 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Supplemental Figure 1
View article: Supplemental Figure 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Supplemental Figure 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Supplemental Figure 3
View article: DCE-Qnet: deep network quantification of dynamic contrast enhanced (DCE) MRI
DCE-Qnet: deep network quantification of dynamic contrast enhanced (DCE) MRI Open
View article: Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer Open
Purpose: Patients with microsatellite instability–high/mismatch repair-deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab. We define the genomic features, clinical course, and …
View article: Pictorial review of multiparametric MRI in bladder urothelial carcinoma with variant histology: pearls and pitfalls
Pictorial review of multiparametric MRI in bladder urothelial carcinoma with variant histology: pearls and pitfalls Open
View article: Deep Learning Prostate MRI Segmentation Accuracy and Robustness: A Systematic Review
Deep Learning Prostate MRI Segmentation Accuracy and Robustness: A Systematic Review Open
Purpose To investigate the accuracy and robustness of prostate segmentation using deep learning across various training data sizes, MRI vendors, prostate zones, and testing methods relative to fellowship-trained diagnostic radiologists. Ma…
View article: The Prevalence and Radiologic Features of Renal Cancers Associated with <i>FLCN, BAP1, SDH</i>, and <i>MET</i> Germline Mutations
The Prevalence and Radiologic Features of Renal Cancers Associated with <i>FLCN, BAP1, SDH</i>, and <i>MET</i> Germline Mutations Open
Purpose To investigate the prevalence of FLCN, BAP1, SDH, and MET mutations in an oncologic cohort and determine the prevalence, clinical features, and imaging features of renal cell carcinoma (RCC) associated with these muta…
View article: Prostate Cancer Screening With MRI: Lessons Learned From Repeat Rounds of the GÖTEBORG-2 and STHLM3-MRI Trials
Prostate Cancer Screening With MRI: Lessons Learned From Repeat Rounds of the GÖTEBORG-2 and STHLM3-MRI Trials Open
View article: Inguinal lymph node metastases from prostate cancer: clinical, pathology, and multimodality imaging considerations
Inguinal lymph node metastases from prostate cancer: clinical, pathology, and multimodality imaging considerations Open
Objective: To investigate clinical, pathology, and imaging findings associated with inguinal lymph node (LN) metastases in patients with prostate cancer (PCa). Materials and Methods: This was a retrospective single-center study of patients…
View article: Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI
Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI Open
View article: Mentorship in Radiology Research: A Guide for Mentors and Mentees
Mentorship in Radiology Research: A Guide for Mentors and Mentees Open